AU2021211146A1 - Complex of 7-deacetyforskoline and PVP - Google Patents

Complex of 7-deacetyforskoline and PVP Download PDF

Info

Publication number
AU2021211146A1
AU2021211146A1 AU2021211146A AU2021211146A AU2021211146A1 AU 2021211146 A1 AU2021211146 A1 AU 2021211146A1 AU 2021211146 A AU2021211146 A AU 2021211146A AU 2021211146 A AU2021211146 A AU 2021211146A AU 2021211146 A1 AU2021211146 A1 AU 2021211146A1
Authority
AU
Australia
Prior art keywords
dafsk
pvp
complex
mixture
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021211146A
Other languages
English (en)
Inventor
Andreas Kubin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scipharm SARL
Original Assignee
Scipharm SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scipharm SARL filed Critical Scipharm SARL
Publication of AU2021211146A1 publication Critical patent/AU2021211146A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
AU2021211146A 2020-01-23 2021-01-22 Complex of 7-deacetyforskoline and PVP Pending AU2021211146A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20153429.4 2020-01-23
EP20153429 2020-01-23
PCT/EP2021/051499 WO2021148633A1 (de) 2020-01-23 2021-01-22 Komplex aus 7-deacetylforskolin und pvp

Publications (1)

Publication Number Publication Date
AU2021211146A1 true AU2021211146A1 (en) 2022-09-01

Family

ID=69190714

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021211146A Pending AU2021211146A1 (en) 2020-01-23 2021-01-22 Complex of 7-deacetyforskoline and PVP

Country Status (18)

Country Link
US (1) US20230346956A1 (ja)
EP (1) EP4093374B1 (ja)
JP (1) JP2023511432A (ja)
AU (1) AU2021211146A1 (ja)
BR (1) BR112022014362A2 (ja)
CA (1) CA3166464A1 (ja)
DK (1) DK4093374T3 (ja)
ES (1) ES2969594T3 (ja)
FI (1) FI4093374T3 (ja)
HR (1) HRP20240181T1 (ja)
HU (1) HUE065181T2 (ja)
IL (1) IL294848A (ja)
LT (1) LT4093374T (ja)
PL (1) PL4093374T3 (ja)
PT (1) PT4093374T (ja)
RS (1) RS65265B1 (ja)
SI (1) SI4093374T1 (ja)
WO (1) WO2021148633A1 (ja)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1294205B1 (it) 1997-07-23 1999-03-24 Farmigea Spa Procedimento per la solubilizzazione in acqua e in veicoli acquosi di sostanze farmacologicamente attive
US6960300B2 (en) 2003-09-08 2005-11-01 Sami Labs Limited Process for preparing water soluble diterpenes and their applications
WO2017103840A1 (en) 2015-12-16 2017-06-22 MOHAMED ABDULLA ANZAR, Cheppattu A water soluble 10% w/w forskolin composition and a method of synthesizing the same
PL3565602T3 (pl) 2017-01-09 2021-09-13 SciPharm S.à r.l. Nowy sposób wytwarzania rozpuszczalnej w wodzie forskoliny

Also Published As

Publication number Publication date
WO2021148633A1 (de) 2021-07-29
PT4093374T (pt) 2024-01-23
RS65265B1 (sr) 2024-03-29
EP4093374A1 (de) 2022-11-30
LT4093374T (lt) 2024-03-12
BR112022014362A2 (pt) 2022-09-13
PL4093374T3 (pl) 2024-04-15
CA3166464A1 (en) 2021-07-29
HRP20240181T1 (hr) 2024-04-26
SI4093374T1 (sl) 2024-03-29
EP4093374B1 (de) 2023-11-15
US20230346956A1 (en) 2023-11-02
FI4093374T3 (fi) 2024-02-06
ES2969594T3 (es) 2024-05-21
DK4093374T3 (da) 2024-02-05
IL294848A (en) 2022-09-01
HUE065181T2 (hu) 2024-05-28
JP2023511432A (ja) 2023-03-17

Similar Documents

Publication Publication Date Title
EP2244712B1 (en) In vivo studies of crystalline forms of meloxicam
EP2818169B1 (en) Conjugate of polyethylene glycol and naloxone, pharmaceutical composition and use thereof
JP6960853B2 (ja) (6s)−5−メチルテトラヒドロ葉酸又はその塩の組成物及びその調製と応用
US20100029667A1 (en) Spray dried formulation
HRP20050205A2 (en) Benzensulfonate of 4-fluoro-2-cyanopyrrolidine derivative
NZ583269A (en) Novel forms of cddo methyl ester also known as methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28 oate
TW201032814A (en) Low-molecular-weight polysulfated hyaluronic acid derivative and pharmaceutical containing the same
CN109678715B (zh) 2-(1-酰氧正戊基)苯甲酸与碱性氨基酸或氨基胍形成的盐、其制备方法及用途
EP3127909A1 (en) Crystalline forms of rifaximin and their preparation in the presence of amino acids
JP2016525528A (ja) 非晶質形態のダサチニブの塩
JP5425799B2 (ja) 抗腫瘍活性を有する水溶性トリテルペンフェノール化合物及びその調製方法
KR101986983B1 (ko) 망기페린-6-o-베르베린염 수화물 및 그 제조방법과 용도
JP2023164361A (ja) イオン化可能な脂質化合物
JP2014144916A (ja) 2−アシルアミノチアゾール化合物の結晶
RU2485121C1 (ru) Новые кристаллические формы адефовира дипивоксила и способы его получения
EP1311506B1 (en) Chiral fluoroquinolizinone arginine salt forms
US20230346956A1 (en) Complex of 7-deacetylforskolin and pvp
EA044513B1 (ru) Комплекс 7-дезацетил-форсколина и пвп
JP2003505338A (ja) 高いトリヒドロキシ−エチル−ルチン濃度のトロキセルチン及びその合成方法
TW200538457A (en) Aqueous solutions comprising camptothecin
JP2001500526A (ja) 粘液溶解剤としての2−メチル−チアゾリジン−2,4−ジカルボン酸の使用
SI21748A (sl) Inkluzijski kompleksi klopidogrela in njegovih kislinskih adicijskih soli, postopek za njihovo pripravo, farmacevtski pripravki, ki vsebujejo te komplekse in njihova uporaba za zdravljenje tromboze
KR101770014B1 (ko) 아미노벤조산 유도체의 유기 아민염 및 그 제조 방법
KR100318785B1 (ko) 티아졸리딘유도체
AU2015200516B2 (en) Novel forms of CDDO methyl ester